Literature DB >> 10984641

Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease.

A Leake1, C M Morris, J Whateley.   

Abstract

Several lines of evidence indicate that there may be an inflammatory component to the pathology of Alzheimer's disease (AD), the major form of degenerative dementia in the elderly. Activity of inflammatory cells, and the elaboration of toxic molecules by such cells may be a significant factor in disease progression. In peripheral inflammatory states, the increased activity of matrix metalloproteinase (MMP) enzymes are a major cause of tissue breakdown and secondary damage in diseases such as rheumatoid arthritis. The activity of such enzymes in the normal or diseased central nervous system is, however, not well characterized. We have therefore determined the levels of MMP 1 (collagenase) in the normal human brain and in AD. MMP1 levels were relatively low though were significantly elevated by approximately 50% in AD in all cortical areas examined. Given the activity towards collagen of MMP1, it is possible that enhanced MMP1 activity in AD, may contribute to the blood-brain barrier dysfunction seen in AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984641     DOI: 10.1016/s0304-3940(00)01418-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

Review 1.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

2.  Metalloendoprotease cleavage triggers gelsolin amyloidogenesis.

Authors:  Lesley J Page; Ji Young Suk; Mary E Huff; Hee-Jong Lim; John Venable; John Yates; Jeffery W Kelly; William E Balch
Journal:  EMBO J       Date:  2005-11-10       Impact factor: 11.598

3.  Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw.

Authors:  Joanne M Ajmo; Lauren A Bailey; Matthew D Howell; Lisa K Cortez; Keith R Pennypacker; Hina N Mehta; Dave Morgan; Marcia N Gordon; Paul E Gottschall
Journal:  J Neurochem       Date:  2010-02-17       Impact factor: 5.372

4.  Metabolic Dysfunction of Astrocyte: An Initiating Factor in Beta-amyloid Pathology?

Authors:  Liang-Jun Yan; Ming Xiao; Ran Chen; Zhiyou Cai
Journal:  Aging Neurodegener       Date:  2013-08

Review 5.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 6.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

7.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides.

Authors:  Tao Jiang; Emilia S Olson; Quyen T Nguyen; Melinda Roy; Patricia A Jennings; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

8.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  Stefan Lorenzl; Noel Calingasan; Lichuan Yang; David S Albers; Shuei Shugama; Jason Gregorio; H W Krell; Jason Chirichigno; Tong Joh; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

9.  Matrix metalloproteinases in cerebral ischemia.

Authors:  Hahn Young Kim; Seol-Heui Han
Journal:  J Clin Neurol       Date:  2006-09-20       Impact factor: 3.077

Review 10.  Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.

Authors:  Jack Cheng; Hsin-Ping Liu; Cheng-Chun Lee; Mei-Ying Chen; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  Neurol Sci       Date:  2017-11-04       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.